Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809819 | 1.00 | HSD17B10 (0.47) | HSD17B10USP2ALDH1A1HPGDLMNA | |
| SCHEMBL4429 | 1.00 | HSD17B10 (0.47) | HSD17B10USP2ALDH1A1HPGDLMNA | |
| SCHEMBL13547538 | 0.82 | DDB1 (0.39) | HSD17B10USP2ALDH1A1HPGDLMNA | |
| SCHEMBL9243943 | 0.81 | MAOB (0.44) | LMNAMAOBPKMMAOA | |
| SCHEMBL9109652 | 0.81 | MAOB (0.44) | LMNAMAOBPKMMAOA | |
| SCHEMBL2722147 | 0.81 | SLC6A3 (0.46) | — | |
| SCHEMBL2901706 | 0.81 | SLC6A3 (0.46) | — | |
| SCHEMBL5021254 | 0.81 | MAOB (0.44) | MAOB | |
| SCHEMBL20840267 | 0.81 | DDB1 (0.40) | HSD17B10USP2ALDH1A1HPGDMAOB | |
| SCHEMBL8234131 | 0.81 | USP2 (0.35) | HSD17B10USP2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136861-A | 2-Aryl-6-aryloxy methylmorpholine derivative and application thereof | 安徽景星医药技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115043810-B | Method for preparing chiral hydrocarbon bond oxidation product by non-metal catalyzed asymmetric hydrocarbon bond oxidation | 浙江大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-115043810-A | Method for preparing chiral carbon-hydrogen bond oxidation product by non-metal catalyzed asymmetric carbon-hydrogen bond oxidation | 浙江大学 | 2022-09-13 | — | — | CN | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2638022-B1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| EP-1994016-A2 | 5-PHENYL-3-BENZYL-OXAZOLIDIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
| EP-1008590-B1 | Process for preparing optically active oxazolidinone derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-6403804-B1 | ALLOWING HYDRAZINE TO REACT ON OPTICALLY ACTIVE ACID ESTER HAVING HYDROXYL GROUP AT 3-POSITION TO GIVE OPTICALLY ACTIVE HYDRAZIDE HAVING HYDROXYL GROUP AT 3-POSITION, SUBJECTING OPTICALLY ACTIVE HYDRAZIDE TO CURTIUS REARRANGEMENT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1008590-A1 | Process for preparing optically active oxazolidinone derivative | Takasago International Corporation (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | HSD17B10 310/4885USP2 1905/4885ALDH1A1 3887/4885 |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | HSD17B10 2337/4885USP2 4248/4885ALDH1A1 1329/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | HSD17B10 2337/4885USP2 4248/4885ALDH1A1 1329/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | HSD17B10 310/4885USP2 1905/4885ALDH1A1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.